AstraZeneca Pharma India Limited

Symbol: ASTRAZEN.BO

BSE

5110.6

INR

Market price today

  • 92.1069

    P/E Ratio

  • 3.5268

    PEG Ratio

  • 127.77B

    MRK Cap

  • 0.00%

    DIV Yield

AstraZeneca Pharma India Limited (ASTRAZEN-BO) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.54%

Operating Profit Margin

0.12%

Net Profit Margin

0.12%

Return on Assets

0.00%

Return on Equity

0.45%

Return on Capital Employed

0.00%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Dr. Sanjeev Kumar Panchal
Full-time employees:947
City:Bengaluru
Address:Manyata Embassy Business Park
IPO:2000-07-10
CIK:

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brand names; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brand names. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

General Outlook

When we look at how much money they make before expenses, they keep 0.545% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.123%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.116%. This tells us they're good at keeping money after all costs.

Return on Investments

AstraZeneca Pharma India Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.448%.

Stock Prices

AstraZeneca Pharma India Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $5389.45, while its low point bottomed out at $5159.05. This variance in figures offers investors a lucid insight into the roller-coaster ride that is AstraZeneca Pharma India Limited's stock market.

Profitability Ratios

ASTRAZEN.BO profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 15.74% underscores its earnings before tax deductions. The effective tax rate stands at 26.09%, revealing its tax efficiency. The net income per EBT, 73.92%, and the EBT per EBIT, 127.97%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 12.30%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin15.74%
Effective Tax Rate26.09%
Net Income per EBT73.92%
EBT per EBIT127.97%
EBIT per Revenue12.30%

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 60.53, and free cash flow per share, 60.53, depict cash generation on a per-share basis. Lastly, the operating cash flow sales ratio, 0.13, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share60.53
Free Cash Flow per Share60.53
Operating Cash Flow Sales Ratio0.13
Free Cash Flow to Operating Cash Flow Ratio1.00

Debt and Leverage Ratios

An interest coverage of 108.98 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Interest Coverage108.98

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 401.19, provides a glimpse into top-line earnings distributed across each share. Net income per share, 39.72, reflects the portion of profit attributed to each share. The book value per share, 235.48, represents the net asset value distributed per share, while the tangible book value per share, 235.48, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share401.19
Net Income Per Share39.72
Book Value Per Share235.48
Tangible Book Value Per Share235.48
Shareholders Equity Per Share235.48
Interest Debt Per Share3.14
Capex Per Share-3.41

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 24.50%, indicates top-line expansion, while the gross profit growth, 28.91%, reveals profitability trends. EBIT growth, 111.38%, and operating income growth, 111.38%, offer insights into operational profitability progression. The net income growth, 61.19%, showcases bottom-line expansion, and the EPS growth, 61.20%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth24.50%
Gross Profit Growth28.91%
EBIT Growth111.38%
Operating Income Growth111.38%
Net Income Growth61.19%
EPS Growth61.20%
EPS Diluted Growth61.20%
Dividends per Share Growth300.00%
Operating Cash Flow Growth-42.17%
Free Cash Flow Growth-45.42%
10-Year Revenue Growth per Share157.00%
5-Year Revenue Growth per Share75.65%
3-Year Revenue Growth per Share20.58%
10-Year Operating CF Growth per Share1065.70%
5-Year Operating CF Growth per Share563.14%
3-Year Operating CF Growth per Share-33.32%
10-Year Net Income Growth per Share210.90%
5-Year Net Income Growth per Share283.21%
3-Year Net Income Growth per Share37.50%
10-Year Shareholders Equity Growth per Share490.15%
5-Year Shareholders Equity Growth per Share138.40%
3-Year Shareholders Equity Growth per Share61.53%
10-Year Dividend per Share Growth per Share124.48%
3-Year Dividend per Share Growth per Share700.00%
Receivables Growth20.32%
Inventory Growth35.65%
Asset Growth14.98%
Book Value per Share Growth15.12%
Debt Growth-16.45%
R&D Expense Growth50.96%
SGA Expenses Growth13.13%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 76,251,200,000, captures the company's total value, considering both debt and equity. Income quality, 0.43, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.03, gauges operational efficiency, while the research and development to revenue, 5.90%, highlights investment in innovation. The ratio of intangibles to total assets, 5.54%, indicates the value of non-physical assets, and capex to operating cash flow, -14.62%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value76,251,200,000
Income Quality0.43
Sales General and Administrative to Revenue0.03
Research and Development to Revenue5.90%
Intangibles to Total Assets5.54%
Capex to Operating Cash Flow-14.62%
Capex to Revenue-0.85%
Capex to Depreciation-52.40%
Stock-Based Compensation to Revenue0.24%
Graham Number458.72
Return on Tangible Assets10.67%
Graham Net Net119.49
Working Capital4,515,400,000
Tangible Asset Value5,341,227,000
Net Current Asset Value4,392,900,000
Average Receivables1,083,200,000
Average Payables2,091,600,000
Average Inventory1,652,150,000
Days Sales Outstanding43
Days Payables Outstanding196
Days of Inventory On Hand163
ROIC18.76%
ROE0.17%

Valuation Ratios

The price to sales ratio, 10.72, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 84.78, and price to operating cash flows, 84.78, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price to Sales Ratio10.72
Price Cash Flow Ratio84.78
Price Earnings to Growth Ratio3.53
Enterprise Value Multiple67.96
Price to Operating Cash Flow Ratio84.78
Price to Free Cash Flows Ratio84.78
Price to Tangible Book Ratio13.79
Enterprise Value to Sales7.60
Enterprise Value Over EBITDA40.40
EV to Operating Cash Flow130.81
Earnings Yield1.22%
Free Cash Flow Yield0.61%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of AstraZeneca Pharma India Limited (ASTRAZEN.BO) on the BSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 92.107 in 2024.

What is the ticker symbol of AstraZeneca Pharma India Limited stock?

The ticker symbol of AstraZeneca Pharma India Limited stock is ASTRAZEN.BO.

What is company IPO date?

IPO date of AstraZeneca Pharma India Limited is 2000-07-10.

What is company current share price?

Current share price is 5110.600 INR.

What is stock market cap today?

The market cap of stock today is 127765000000.000.

What is PEG ratio in 2024?

The current 3.527 is 3.527 in 2024.

What is the number of employees in 2024?

In 2024 the company has 947.